Auro Laboratories Ltd vs Sanofi India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Auro Laboratories Ltd is ₹ 239.1 as of 30 Apr 15:30 . The P/E Ratio of Auro Laboratories Ltd is 0 as of December 2023 .The P/E Ratio of Sanofi India Ltd is 30.8 as of December 2023 . The Market Cap of Auro Laboratories Ltd is ₹ 0 crore as of December 2023 .The Market Cap of Sanofi India Ltd is ₹ 18578 crore as of December 2023 . The revenue of Auro Laboratories Ltd for the Sep '25 is ₹ 9.81 crore as compare to the Jun '25 revenue of ₹ 3.19 crore. This represent the growth of 207.52% The revenue of Sanofi India Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Auro Laboratories Ltd for the Sep '25 is ₹ 3.33 crore as compare to the Jun '25 ebitda of ₹ 0.45 crore. This represent the growth of 640% The ebitda of Sanofi India Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Auro Laboratories Ltd changed from ₹ 0.75 crore to ₹ 0.72 crore over 5 quarters. This represents a CAGR of -3.21% The net profit of Sanofi India Ltd changed from ₹ 136.6 crore to ₹ 0 crore over 5 quarters. This represents a CAGR of -100.00% The dividend payout of Auro Laboratories Ltd changed from 0 % to 0 % over 10 quarters. This represents a CAGR of 0.0% The dividend payout of Sanofi India Ltd changed from 119.34 % to 0 % over 10 quarters. This represents a CAGR of -100.00% .

About Auro Laboratories Ltd

Auro Laboratories Limited, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API).
Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes.
The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra.
The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards.
Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company's primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments.

About Sanofi India Ltd

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956.
The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.
The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market.
The Company is primarily engaged in the business of manufacturing and trading of drugs s and pharmaceuticals.
It has its own manufacturing facility at Goa.

FAQs for the comparison of Auro Laboratories Ltd and Sanofi India Ltd

Which company has a larger market capitalization, Auro Laboratories Ltd or Sanofi India Ltd?

Market cap of Auro Laboratories Ltd is 149 Cr while Market cap of Sanofi India Ltd is 8,111 Cr

What are the key factors driving the stock performance of Auro Laboratories Ltd and Sanofi India Ltd?

The stock performance of Auro Laboratories Ltd and Sanofi India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Auro Laboratories Ltd and Sanofi India Ltd?

As of May 3, 2026, the Auro Laboratories Ltd stock price is INR ₹239.1. On the other hand, Sanofi India Ltd stock price is INR ₹3522.25.

How do dividend payouts of Auro Laboratories Ltd and Sanofi India Ltd compare?

To compare the dividend payouts of Auro Laboratories Ltd and Sanofi India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.